Buy Crypto
Markets
Spot
FuturesBTC
Earn
Event Center
Rewards Hub
More
100%+ PoR
NTLA

Intellia Therapeutics, Inc. (NTLA)

NASDAQ
$9.77
-$0.00
(-0.05%)
Previous Close: ⁦$9.78⁩
Market Closed

Last updated: ⁦2026-11-19 02:40:40⁩. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.

Summary

Intellia Therapeutics, Inc. (NTLA) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $9.77, with a market capitalization of $1.38B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.95 to $18.48. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

$1.38B

$9.87

$10.47

$9.66

$9.78

5.28M

4.73M

--

$18.48

$7.95

--

2026-09-30

Intellia Therapeutics, Inc. (NTLA) Latest Closing Stock Price

Intellia Therapeutics, Inc. (NTLA) last closed at $9.77 as of 2026-11-19 01:00:00, down 0.05% ($0.00) from the previous close of $9.78.

During the latest regular trading session, NTLA traded between $9.67 and $10.47, with a volume of 5.28M shares. The closing price was near the lower end and near the lower end of its 52-week range.

Intellia Therapeutics, Inc. (NTLA) 7-Day Stock Price Change

Over the past seven days, Intellia Therapeutics, Inc. (NTLA) moved from $12.11 to $9.77, representing a decline of 19.34% ($2.34).

The stock traded between $9.67 and $12.15 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.

The average daily volume was 5.87 million shares, up versus the previous seven-day period, indicating higher trading activity.

NTLA 52-Week Price Position

Position in Range: 17.3%

52W Low$7.95
52W High$18.48

NTLA is currently trading at $9.77, placing it 17.3% of the way from its 52-week low of $7.95 to its 52-week high of $18.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Intellia Therapeutics, Inc. (NTLA)?

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics, Inc. Information

Industry
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees
377
Exchange
NASDAQ
Company Website

NTLA News

Latest news related to Intellia Therapeutics, Inc. and NTLA stock.

  • Benzinga

    Intellia Reiterates Lonvo-Z PDUFA Date Of 10 Mar 2027

    Read Full Article
  • Benzinga

    Intellia Says HAELO Met Key Secondary Quality-Of-Life Endpoint; No Serious Adverse Events In Lonvo-Z Arm

    Read Full Article
  • Benzinga

    Intellia Says 89% Overall Attack Rate Reduction Across 93 Patients Over Up To 4 Years After One-Time Lonvo-Z Dose; All LTP-Free At Latest Follow-Up

    Read Full Article
  • Benzinga

    Intellia Says Lonvo-Z Cut HAE Attack Rate 81% Vs Prior Long-Term Prophylaxis In Phase 3 HAELO Patients

    Read Full Article
  • Massive

    Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026

    Intellia Therapeutics announced positive clinical data for lonvo-z, its one-time CRISPR gene editing treatment for hereditary angioedema (HAE), presented at ACAAI 2026. Key findings include an 81% reduction in monthly attack rates for patients previously on long-term prophylaxis, with 100% of patients becoming prophylaxis-free. Patient interviews showed 96% described lonvo-z as optimal therapy. The FDA accepted the BLA with Priority Review and a PDUFA target action date of March 10, 2027.

    Read Full Article

Ways to Trade NTLA at MEXC

NTLA MEXC RealStocks

Own real NTLA shares through MEXC's regulated brokerage partner.


Suitable for long-term holding.

  • Own the actual shares
  • Receive dividends and voting rights
  • Buy fractional shares starting at $1

How to Buy Intellia Therapeutics, Inc. (NTLA) Stock on MEXC

Eligible investors can buy real shares of Intellia Therapeutics, Inc. (NTLA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account
Step 1: Open and Verify Your RealStocks Account
Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.
Step 2: Transfer USDT to Your RealStocks Account
Step 2: Transfer USDT to Your RealStocks Account
Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.
Step 3: Search for NTLA and Place Your Order
Step 3: Search for NTLA and Place Your Order
Open the RealStocks trading page and search for NTLA. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Intellia Therapeutics, Inc. (NTLA) stock price today?
Intellia Therapeutics, Inc. (NTLA) is currently trading at $9.77, down 0.05% ($0.00) from the previous close of $9.78. Intraday prices update in real time during regular trading hours.
2.Is NTLA stock going up or down today?
As of 2026-11-19 01:00:00, NTLA is trading at $9.77, down 0.05% ($0.00) from its previous close of $9.78. The stock has traded between $9.67 and $10.47 during today’s regular session. Past price movements do not guarantee future results.
3.What is NTLA pre-market price?
As of 2026-11-19 01:00:00, NTLA is trading at $9.88 in pre-market trading, up 1.00% ($0.10) from the previous close of $9.78. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.
4.What is NTLA after-hours price?
As of 2026-11-19 01:00:00, NTLA is trading at $9.96 in after-hours trading, up 1.91% ($0.19) from the regular-session close of $9.77. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.
5.Is NTLA stock trading now?
NTLA trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.
6.Where does NTLA sit relative to its 52-week high and low?
Over the past 52 weeks, NTLA has traded between a low of $7.95 and a high of $18.48. At $9.77, the stock is positioned 17.3% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.
7.What sector is Intellia Therapeutics, Inc. in?
Intellia Therapeutics, Inc. (NTLA) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.
8.What is Intellia Therapeutics, Inc.'s market capitalization and where is it listed?
Intellia Therapeutics, Inc. is listed on the NASDAQ exchange with a market capitalization of $1.38B. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.
9.How is NTLA valued in terms of P/E ratio and EPS?
NTLA trades at a P/E ratio of --, based on trailing-twelve-month EPS of $-3.04. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.
10.Does Intellia Therapeutics, Inc. pay a dividend?
Intellia Therapeutics, Inc. pays an indicated annual cash dividend of $0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.

Explore More US Stocks

Stocks in the Same Sector

Browse other US stocks in the same sector as Intellia Therapeutics, Inc.

Largest Market Cap

See US stocks with the highest market capitalization

Most Actively Traded

Discover today's most actively traded US stocks

Top 5 Cryptocurrencies

Explore the cryptocurrencies with the highest market capitalization

Compliance Disclosure and Data Source

Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to NTLA, including Stocks, Tokenized Stocks, and Stock Futures.

Disclaimer

The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.

Search Stocks

NTLA Stock Calculator

Estimate the value between NTLA shares and USD.

NTLA Shares to USD

NTLA Shares
NTLA
NTLA
USD
USD
USD

1.00 NTLA shares = 9.768 USD

Calculations are estimates based on the latest available price and are for reference only.